Radioimmunotherapy (I): Development of Radioimmunoconjugates.
- Author:
Tae Hyun CHOI
1
;
Sang Moo LIM
Author Information
1. Nuclear Medicine Laboratory, Korean Institute of Radiological and Medical Science, Seoul, Korea. smlim328@kcch.re.kr
- Publication Type:Clinical Trial ; Review
- Keywords:
radioimmunotherapy;
radio isotope;
monoclonal antibody;
clinical trial
- MeSH:
Antibodies, Monoclonal;
Hematologic Neoplasms;
Immunoconjugates*;
Radioimmunotherapy*;
Thyroid Neoplasms;
Rituximab
- From:Nuclear Medicine and Molecular Imaging
2006;40(2):66-73
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Monoclonal antibodies are designed to bind specifically to certain antigen, give therapeutic effect to the target and to be produced in large scale with homogeneity. The monoclonal antibodies conjugated with radionuclide can deliver therapeutic irradiation to the target, and showed successful results in certain malignancies, which is known as radioimmunotherapy. The target-to-background ratio depends on the antigen expression in the target and normal tissues, which is related to the therapeutic efficacy and toxicity in radioimmunotherapy. For the solid tumor beta-ray energy should be high, but lower beta energy is better for the hematological malignancies. I-131 is widely used in thyroid cancer with low cost and high availability. Labeling monoclonal antibody with I-131 is relatively simple and reproducible. Some preclinical data for the I-131 labeled monoclonal antibodies including acute toxicity and efficacy are available from already published literatures. In KIRAMS, physician sponsored clinical trial protocols using Rituximab, KFDA approved anti-CD20 chimeric monoclonal antibody and I-131 were approved by KFDA and currently are ongoing.
